BillionToOne

The Top Healthcare Technology Companies of 2026: Volume I Medical science has advanced to a point previously thought unimaginable, with breakthrough therapies, complex genomic mapping, and highly precise diagnostics rewriting what is possible in patient care. Yet as clinical capabilities leap forward, other parts of the industry are racing to keep pace. Noom, BillionToOne, H1, Ardelyx, Inc., ROM Technologies, Inc., Qventus, Inc, AKASA, Remington Medical Inc., Digbi Health, Predoc, and Watershed Health. Read the full article: https://lnkd.in/dZaaTJu9 Sign up for our free email newsletter at https://lnkd.in/gNfBS6g #healthtech #healthcare #technology

For decades, capturing intact fetal cells non-invasively was considered an elusive holy grail in prenatal genetics. Something theoretically possible, but practically out of reach. Today, that changes. We are so proud to announce the launch of Unity Confirm™, the first-and-only non-invasive confirmatory test for high-risk Unity Aneuploidy™ Screen results. Powered by Fetal Cell Capture™ technology, Unity Confirm isolates intact circulating fetal cells from a simple maternal blood draw and delivers CVS-like insights without procedural risk, bridging the gap between prenatal screening and invasive diagnostics. For the first time, this technology is broadly accessible. Read the full press release here: https://lnkd.in/ghWFjSNw #unitycapture

Tonight is the night. Unity's most significant reveal is here, you won’t want to miss it. Join us at 5:30pm EST at ACOG, or tune in virtually at 6pm EST, to see how we're bridging the gap between prenatal screening and invasive diagnostics. unityscreen.com/capture #unitycapture #acog2026

Year after year, Unity has redefined prenatal care. What comes next is the most significant advancement the field has seen in a decade. Be among the first to learn about it at ACOG 2026 or virtually. Join Us. unityscreen.com/capture

1 in 11 babies born in America this year will be screened by a genetic test that didn't exist a decade ago. Biotech startup BillionToOne turned a simple but radical idea—detecting rare fragments of fetal DNA in a mother's blood—into one of the most widely used prenatal tests in the U.S. And they're not stopping there. The same approach could unlock something even bigger: early-stage cancer detection from a blood test, a breakthrough that could one day save millions of lives. In this episode of Hard Tech, YC's Jared Friedman sits down with founders David Tsao and Oguzhan Atay, PhD to hear how they went from half a lab bench to a $4B biotech company—and why they believe this is just the beginning of what their technology can do. Tune in: https://lnkd.in/ghHGcqFx

We're thrilled to welcome Allen Chen, MD as VP of Medical Affairs and Clinical Development, Oncology at BillionToOne! Dr. Chen brings 20+ years as a physician-executive and clinician-scientist across UCLA, UC Davis, UC Irvine, and the University of Kansas Cancer Center, with 300+ peer-reviewed publications and having served as principal investigator for dozens of clinical trials. He'll lead medical affairs strategy as well as clinical translational research development for our Northstar Oncology by BillionToOne portfolio, including Northstar Select® and Northstar Response®. We're also grateful to Gary Palmer, MD, who is retiring and transitioning into a CMO advisory role. His impact on this company and our patients is immeasurable. Read more about the news here: https://lnkd.in/em6wqe4D